Developing novel blood‐based biomarkers for Alzheimer's disease

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Alzheimer's & Dementia

• Publication date

  2014-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.jalz.2013.10.007PMID 24365657PMCID PMC4769619
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Plos One

  2015cited by this paper
• The future of blood‐based biomarkers for Alzheimer's disease

  2014cited by this paper
• Identification of Altered Metabolic Pathways in Plasma and CSF in Mild Cognitive Impairment and Alzheimer’s Disease Using Metabolomics

  2013cited by this paper
• Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.

  2013cited by this paper
• Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium

  2013cited by this paper
• Microglia and macrophages of the central nervous system: the contribution of microglia priming and systemic inflammation to chronic neurodegeneration

  2013cited by this paper
• An Enzyme-Generated Fragment of Tau Measured in Serum Shows an Inverse Correlation to Cognitive Function

  2013cited by this paper
• Gene Expression Profiling of Peripheral Blood Leukocytes Shows Consistent Longitudinal Downregulation of TOMM40 and Upregulation of KIR2DL5A, PLOD1, and SLC2A8 Among Fast Progressors in Early Alzheimer's Disease

  2013cited by this paper
• Several Direct and Calculated Biomarkers from the Amyloid-β Pool in Blood are Associated with an Increased Likelihood of Suffering from Mild Cognitive Impairment

  2013cited by this paper
• Immune Profiling in Blood Identifies sTNF-R1 Performing Comparably Well as Biomarker Panels for Classification of Alzheimer's Disease Patients

  2013cited by this paper
• Oligomers, fact or artefact? SDS-PAGE induces dimerization of β-amyloid in human brain samples

  2013cited by this paper
• Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly.

  2013cited by this paper
• O2‐03‐06: An LC‐MS/MS‐based method for quantification of beta‐amyloid‐1‐38, beta‐amyloid‐1‐40 and beta‐amyloid‐1‐42 in the cerebrospinal fluid of Alzheimer's patients and healthy controls

  2012cited by this paper
• Nutrient intake and plasma β-amyloid

  2012cited by this paper
• Will Posttranslational Modifications of Brain Proteins Provide Novel Serological Markers for Dementias?

  2012cited by this paper
• No Diagnostic Value of Plasma Clusterin in Alzheimer's Disease

  2012cited by this paper
• Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease.

  2012cited by this paper
• Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology[S]

  2012cited by this paper
• Plasma Apolipoprotein Levels Are Associated with Cognitive Status and Decline in a Community Cohort of Older Individuals

  2012cited by this paper
• PC‐06: Pharmacological treatment of Alzheimer's disease

  2012cited by this paper
• Variability in Blood-Based Amyloid-β Assays: The Need for Consensus on Pre-Analytical Processing

  2012influential reference
• Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment

  2012cited by this paper
• Validation of AclarusDx™, a Blood-Based Transcriptomic Signature for the Diagnosis of Alzheimer's Disease

  2012cited by this paper
• Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis.

  2012cited by this paper
• A Blood-Based Algorithm for the Detection of Alzheimer’s Disease

  2011cited by this paper
• Neuropathological alterations in Alzheimer disease.

  2011cited by this paper
• Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI

  2011cited by this paper
• Diagnosis of Alzheimer's Disease Based on Disease-Specific Autoantibody Profiles in Human Sera

  2011cited by this paper
• Plasma Biomarkers of Brain Atrophy in Alzheimer's Disease

  2011cited by this paper
• A Blood-Based Screening Tool for Alzheimer's Disease That Spans Serum and Plasma: Findings from TARC and ADNI

  2011cited by this paper
• Diagnosis of Parkinson's Disease Based on Disease-Specific Autoantibody Profiles in Human Sera

  2011cited by this paper
• A Novel Blood Test for the Early Detection of Alzheimer's Disease

  2011cited by this paper
• Identification of a blood-based biomarker panel for classification of Alzheimer's disease.

  2011cited by this paper
• Serum clusterin levels are not increased in presymptomatic Alzheimer's disease.

  2011cited by this paper
• Plasma clusterin and the risk of Alzheimer disease.

  2011cited by this paper
• P2‐033: Plasma amyloid‐beta as a predictor of dementia and cognitive decline: A systematic review and meta‐analysis

  2011cited by this paper
• Comparison of Conventional ELISA with Electrochemiluminescence Technology for Detection of Amyloid-β in Plasma

  2010cited by this paper
• An inherited variable poly-T repeat genotype in TOMM40 in Alzheimer disease.

  2010cited by this paper
• Neuroinflammatory processes in Alzheimer’s disease

  2010cited by this paper
• A serum protein-based algorithm for the detection of Alzheimer disease.

  2010cited by this paper
• Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss

  2010influential reference
• Alterations of the Sphingolipid Pathway in Alzheimer’s Disease: New Biomarkers and Treatment Targets?

  2010cited by this paper
• A novel Aβ isoform pattern in CSF reflects γ-secretase inhibition in Alzheimer disease

  2010cited by this paper
• Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease.

  2010cited by this paper
• Blood-based biomarkers of Alzheimer's disease: challenging but feasible.

  2010cited by this paper
• Serum sphingomyelins and ceramides are early predictors of memory impairment.

  2010influential reference
• Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes

  2009cited by this paper
• Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease

  2009cited by this paper
• Systemic inflammation and disease progression in Alzheimer disease

  2009cited by this paper
• Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer

  2009cited by this paper
• Identifying Early Markers of Alzheimer's Disease using Quantitative Multiplex Proteomic Immunoassay Panels

  2009cited by this paper
• Markers of endothelial dysfunction in older subjects with late onset Alzheimer's disease or vascular dementia.

  2008cited by this paper
• Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins

  2007cited by this paper
• Evaluating the comparability of gene expression in blood and brain

  2006cited by this paper
• Alzheimer’s Dementia

  1985cited by this paper

• Light-addressable sandwich photoelectrochemical immunosensor array and lateral flow immunoassays with self-calibration using quantum dots-sensitized and porphyrin-engineered MOFs for accurate detection of amyloid β-proteins.

  2026cites this paper
• Modulating Cerebrospinal Fluid Composition in Neurodegenerative Processes: Modern Drug Delivery and Clearance Strategies

  2025cites this paper
• Plasma vs. serum: which is better for proteomic blood biomarker analysis? Evaluation of the novel NULISA platform

  2025cites this paper
• A Multimodal Approach to Alzheimer's Diagnosis: Geometric Insights from Cube Copying and Cognitive Assessments

  2025cites this paper
• “Advances in biomarker discovery and diagnostics for alzheimer’s disease”

  2025cites this paper
• Blood biomarkers of Alzheimer's disease: findings from proteomics.

  2025cites this paper
• Older Amyloid Beta as a Candidate Blood Biomarker of Early Cognitive Decline in the Elderly—A Preliminary Study

  2025cites this paper
• An innovative electrochemiluminescent immunosensor using dual amplified signals from AuNPs@CoSn(OH)6 for the detection of the AD biomarker: amyloid beta 1-40.

  2025cites this paper
• Impaired Synaptic Plasticity Mechanisms in Alzheimer’s Disease

  2025cites this paper
• Drawing the mind: assessing cognitive decline through self-figure drawings

  2025cites this paper
• Potential causal link between antiseizure medication targets and cognitive function: A mendelian randomization study.

  2025cites this paper
• A Critical Appraisal of Blood-Based Biomarkers for Alzheimer's Disease.

  2024cites this paper
• An eye’s look unmasks the mystery: correlation between serum amyloid beta peptide, hippocampal volume and retinal thickness in Alzheimer`s disease

  2024cites this paper
• Electrochemiluminescence biosensor for P-tau217 based on target-induced change of the steric hindrance effect of an antibody-modified electrode

  2024cites this paper
• A streamlined, resource-efficient immunoprecipitation-mass spectrometry method for quantifying plasma amyloid-β biomarkers in Alzheimer’s disease

  2024cites this paper
• Unlocking the Potential of Vessel Density and the Foveal Avascular Zone in Optical Coherence Tomography Angiography as Biomarkers in Alzheimer’s Disease

  2024cites this paper
• Diagnosis and therapy of Alzheimer's disease: Light-driven heterogeneous redox processes.

  2024cites this paper
• Learning semi-supervised enrichment of longitudinal imaging-genetic data for improved prediction of cognitive decline

  2024cites this paper
• Strong cathode electroluminescence biosensor based on CeO2 functionalized PCN-222@Ag NPs for sensitive detection of p-Tau-181 protein.

  2024cites this paper
• Optimized Pre-analytical Handling Protocol for Blood-Based Biomarkers of Alzheimer's Disease.

  2024cites this paper
• Longitudinal MRI analysis using a hybrid DenseNet-BiLSTM method for Alzheimer's disease prediction.

  2024cites this paper
• Investigating metabolic dysregulation in serum of triple transgenic Alzheimer’s disease male mice: implications for pathogenesis and potential biomarkers

  2024cites this paper
• The performance of plasma phosphorylated tau231 in detecting Alzheimer's disease: A systematic review with meta‐analysis

  2023cites this paper
• SERS-Based Optical Nanobiosensors for the Detection of Alzheimer’s Disease

  2023cites this paper
• Identification of novel diagnostic panel for mild cognitive impairment and Alzheimer’s disease: findings based on urine proteomics and machine learning

  2023cites this paper
• Multimodal Identification of Alzheimer's Disease: A Review

  2023cites this paper
• Effect of woohwangchungsimwon and donepezil co-treatment on cognitive function and serum metabolic profiles in a scopolamine-induced model of Alzheimer's disease.

  2023cites this paper
• 2D nanostructures: Potential in diagnosis and treatment of Alzheimer's disease.

  2023cites this paper
• Pre-Analytical Variables Influencing Stability of Blood-Based Biomarkers of Neuropathology

  2023cites this paper
• ML-based methods for detection of AD and MCI using blood biomarkers

  2023cites this paper
• From Recognition to Remedy: The Significance of Biomarkers in Neurodegenerative Disease Pathology

  2023cites this paper
• Impact of pre‐analytical sample handling factors on plasma biomarkers of Alzheimer's disease

  2023cites this paper
• Functional Nanomaterials for the Diagnosis of Alzheimer’s Disease: Recent Progress and Future Perspectives

  2023cites this paper
• Alzheimer’s Disease and Its Possible Evolutionary Origin: Hypothesis

  2023cites this paper
• A two-year longitudinal study of retinal vascular impairment in patients with amnestic mild cognitive impairment

  2022cites this paper
• Nanotechnology for the diagnosis and treatment of Alzheimer's disease: A bibliometric analysis

  2022cites this paper
• Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET

  2022cites this paper
• Sensing red blood cell nano-mechanics: Toward a novel blood biomarker for Alzheimer’s disease

  2022cites this paper
• Clinical relevance of biomarkers, new therapeutic approaches, and role of post-translational modifications in the pathogenesis of Alzheimer’s disease

  2022cites this paper
• Proteomic Discovery and Validation of Novel Fluid Biomarkers for Improved Patient Selection and Prediction of Clinical Outcomes in Alzheimer’s Disease Patient Cohorts

  2022cites this paper
• Plasma tau proteins for the diagnosis of mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis

  2022cites this paper
• Proteomic Profiling of Cerebrospinal Fluid by 16-Plex TMT-Based Mass Spectrometry.

  2021cites this paper
• Fluorescent peptide nanoparticles to detect amyloid-beta aggregation in cerebrospinal fluid and serum for Alzheimer’s disease diagnosis and progression monitoring

  2021cites this paper
• Nanoparticle-Enabled Enrichment of Longitudinal Blood Proteomic Fingerprints in Alzheimer’s Disease

  2021cites this paper
• The pleiotropic beneficial intervention of olive oil intake on the Alzheimer's disease onset via fibrinolytic system.

  2021cites this paper
• A method for diagnosis support of mild cognitive impairment through EEG rhythms source location during working memory tasks

  2021cites this paper
• A Dual-Screening Electrochemiluminescent Aptasensor Based on a Mesoporous Silica Nano-Sieve for Specific Detection of Amyloid-β Monomer

  2021cites this paper
• Erythrocyte sphingolipid species as biomarkers of Alzheimer's disease

  2021cites this paper
• NAD+ supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer’s disease via cGAS–STING

  2021cites this paper
• Diagnostic Accuracy of Blood Biomarkers for Alzheimer's Disease and Amnestic Mild Cognitive Impairment: A Systematic Review and Meta-Analysis.

  2021cites this paper
• Biomarkers for the Clinical Diagnosis of Alzheimer’s Disease: Metabolomics Analysis of Brain Tissue and Blood

  2021cites this paper
• Diagnosis of Alzheimer's disease by MRI images using artificial intelligence

  2021cites this paper
• Detection of retinal and blood Aβ oligomers with nanobodies

  2021cites this paper
• Treatment and Intervention Approaches for the Improvement of Language Abilities in Neurodegenerative Diseases

  2020cites this paper
• Plasma Biomarkers of Alzheimer’s Disease in African Americans

  2020cites this paper
• Immunomodulatory sphingosine-1-phosphates as plasma biomarkers of Alzheimer’s disease and vascular cognitive impairment

  2020cites this paper
• Detection of amyloid-beta by Fmoc-KLVFF self-assembled fluorescent nanoparticles for Alzheimer’s disease diagnosis

  2020cites this paper
• The pathway to secondary prevention of Alzheimer's disease

  2020cites this paper
• Adenosine and Metabotropic Glutamate Receptors Are Present in Blood Serum and Exosomes from SAMP8 Mice: Modulation by Aging and Resveratrol

  2020cites this paper
• Retinal imaging in Alzheimer's and neurodegenerative diseases

  2020cites this paper
• Age-Specific Retinal and Cerebral Immunodetection of Amyloid-β Plaques and Oligomers in a Rodent Model of Alzheimer’s Disease

  2020cites this paper
• Exploring the Potential of Neuroproteomics in Alzheimer's Disease.

  2020cites this paper
• Serum Repressor Element-1 Silencing Transcription Factor Levels in Alzheimer's Patients from a National Institute of Health in Mexico City, Elderly and Young Controls.

  2020cites this paper
• Plasma osteopontin as a biomarker of Alzheimer’s disease and vascular cognitive impairment

  2020cites this paper
• Paper-Based Detection Device for Alzheimer’s Disease—Detecting β-amyloid Peptides (1–42) in Human Plasma

  2020cites this paper
• Proteomics as a reliable approach for discovery of blood-based Alzheimer's disease biomarkers: a systematic review and meta-analysis.

  2020cites this paper
• Steps Towards Developing Effective Treatments for Neuropsychiatric Disturbances in Alzheimer’s Disease: Insights From Preclinical Models, Clinical Data, and Future Directions

  2020cites this paper
• Genome‐wide transcriptome analysis identifies novel dysregulated genes implicated in Alzheimer's pathology

  2020cites this paper
• Single-layer exfoliated reduced graphene oxide-antibody Tau sensor for detection in human serum

  2020cites this paper
• Beta-Amyloid-Dependent miRNAs as Circulating Biomarkers in Alzheimer’s Disease: a Preliminary Report

  2020cites this paper
• Early diagnosis of Alzheimer's disease in blood using a disposable electrochemical microfluidic platform.

  2020cites this paper
• Anatomical and functional changes in the retina in patients with Alzheimer’s disease and mild cognitive impairment

  2020cites this paper
• A different vision of translational research in biomarker discovery: a pilot study on circulatory mitochondrial proteins as Parkinson’s disease potential biomarkers

  2020cites this paper
• Evidence that Brain-Reactive Autoantibodies Contribute to Chronic Neuronal Internalization of Exogenous Amyloid-β1-42 and Key Cell Surface Proteins During Alzheimer’s Disease Pathogenesis

  2020cites this paper
• Translational Neuroscience of Speech and Language Disorders

  2020cites this paper
• Plasma amyloid b 40 / 42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer ’ s disease

  2019cites this paper
• Default Mode Network Connectivity Moderates the Relationship Between the APOE Genotype and Cognition and Individualizes Identification Across the Alzheimer’s Disease Spectrum

  2019cites this paper
• Supervised pathway analysis of blood gene expression profiles in Alzheimer's disease.

  2019cites this paper
• Apolipoprotein E4 Expression Causes Gain of Toxic Function in Isogenic Human Induced Pluripotent Stem Cell-Derived Endothelial Cells.

  2019cites this paper
• CSF and blood Kallikrein-8: a promising early biomarker for Alzheimer’s disease

  2019cites this paper
• Evaluation of Peripheral Immune Dysregulation in Alzheimer’s Disease and Vascular Dementia

  2019cites this paper
• Aβ and tau structure-based biomarkers for a blood- and CSF-based two-step recruitment strategy to identify patients with dementia due to Alzheimer's disease

  2019cites this paper
• Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease

  2019cites this paper
• Cerebrospinal fluids from Alzheimer's disease patients exhibit neurotoxic effects on neuronal cell cultures

  2019cites this paper
• Special Section: Blood-Based Biomarkers for Alzheimer’s Disease & Related Dementias A b and tau structure-based biomarkers for a blood- and CSF-based two-step recruitment strategy to identify patients with dementia due to Alzheimer’s disease

  2019cites this paper
• Alzheimer's disease mechanisms in peripheral cells: Promises and challenges

  2019cites this paper
• Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases

  2019cites this paper
• Long-Term Storage Effects on Stability of Aβ1–40, Aβ1–42, and Total Tau Proteins in Human Plasma Samples Measured with Immunomagnetic Reduction Assays

  2019cites this paper
• microRNA diagnostic panel for Alzheimer's disease and epigenetic trade-off between neurodegeneration and cancer.

  2019cites this paper
• Biomarker-Drug and Liquid Biopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for Alzheimer’s Precision Medicine and Pharmacology

  2019cites this paper
• A Network-Based Perspective in Alzheimer's Disease: Current State and an Integrative Framework

  2019influential citation
• An Investigation of Inflammatory and Metabolic Blood-Based Biomarkers of Cognitive Decline

  2018cites this paper
• Clinical Research on Alzheimer’s Disease: Progress and Perspectives

  2018cites this paper
• The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics

  2018cites this paper
• Circulating APP, NCAM and Aβ serve as biomarkers for Alzheimer's disease.

  2018cites this paper
• Proteomic Approaches for the Discovery of Biofluid Biomarkers of Neurodegenerative Dementias

  2018cites this paper
• Blood-based biomarkers for Alzheimer’s disease: mapping the road to the clinic

  2018cites this paper
• Development of an automated capillary nano-immunoassay—Simple Western assay—to quantify total TDP43 protein in human platelet samples

  2018cites this paper
• Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI)

  2018cites this paper
• Auf dem Weg zur Serumdiagnostik von Demenzerkrankungen

  2018cites this paper